7 November 2017 - - Skokie, Illinois-based gene regulatory and immunotherapeutic drug specialist Exicure, Inc. has closed approximately USD 11.2m in subsequent financing led by Luye Pharma Group and others including Eager Info Investments LTD, Knoll Capital Management and Purple Arch Ventures, the company said.
In the initial closing of this private placement, Exicure raised approximately USD 20.1m, making for a total of approximately USD 31.5m in this financing.
Exicure is a clinical stage biotechnology company developing immunomodulatory and gene regulating drugs against validated targets.
The company's proprietary 3-dimensional, spherical nucleic acid architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Its lead programs address inflammatory diseases, genetic disorders, and oncology. 
Luye Pharma focuses on developing, producing, marketing, and selling innovative pharmaceutical products in the therapeutic areas of oncology, cardiovascular, metabolism and the central nervous system. The company has a portfolio of over 30 products.
The business of Luye Pharma covers global main pharmaceutical markets including China, the US, Europe, Australia, Japan, and South Korean with approximately 4,000 employees.